Chris Benecchi Named Inventiva’s New Chief Operating Officer

Chris Benecchi Named Inventiva’s New Chief Operating Officer Exec-Edge Tue, September 1, 2026 at 12:08 AM GMT+2 1 min read IVA TAK LLY NVO JNJ By Karen Roman Inventiva S. A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company).

Mr. Benecchi will lead the company's operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for the last quarter of 2026, and also prepare for potential commercialization, it stated. "As we approach our Phase 3 readout, we are preparing the company for the next stage of its evolution," said Andrew Obenshain, Inventiva's CEO.

"Chris brings a valuable combination of commercial, operational and launch experience, with a proven track record of helping organizations bring promising medicines to patients. " READ MORE Cocrystal Pharma: The Strategic Reset Investors May Be Missing Mr. Benecchi has 30 years of biopharmaceutical leadership experience across commercial, operational and enterprise roles, with a record of building organizations, preparing investigational medicines for launch, and leading cross-functional execution in competitive and access-challenged markets, Inventiva said.

Mr. Benecchi holds an MBA from Duke University's Fuqua School of Business and a Bachelor of Arts from Colby College. Never Miss our Weekly Highlights  HERE Contact: Exec Edge Editor@executives-edge.

com Click  HERE  to follow us on LinkedIn The post Chris Benecchi Named Inventiva's New Chief Operating Officer appeared first on ExecEdge .